Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Non-small cell lung cancer (NSCLC)

PTK7 protein tyrosine kinase 7 (PTK7; CCK4)

Studies in mice and patient samples suggest inhibiting PTK7 could be useful for treating lung adenocarcinomas. In primary human lung adenocarcinoma samples, compared with normal lung tissue, PTK7 was overexpressed. In a mouse xenograft model of lung adenocarcinoma, shRNA against PTK7 decreased tumor growth compared with control shRNA. Next steps could include screening for and evaluating pharmacological PTK7 inhibitors in mouse models of lung adenocarcinoma.

SciBX 7(16); doi:10.1038/scibx.2014.457
Published online April 24, 2014

Patent and licensing status unavailable

Chen, R. et al. Cancer Res.; published online March 20, 2014;
doi:10.1158/0008-5472.CAN-13-2775
Contact: E. Alejandro Sweet-Cordero, Stanford University, Stanford, Calif.
e-mail:

ascor@stanford.edu